Mlcáková & Babusíková [87] evaluated marker expression on BCP-ALL cells using a five-tube antibody combination (CD20/CD10/CD45/CD19, CD22/CD34/CD45/CD19, CD38/CD34/CD45/CD19, CD58/CD10/CD45, and TdT/CD10/CD45), used for the diagnosis of BCP-ALL patients. Here, CD38 is linked to acute lymphoblastic leukemia.